Log in to your Inderes Free account to see all free content on this page.
AstraZeneca
1,793.50 SEK
+0.73 %
Less than 1K followers
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AstraZeneca
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 136,968.0 | 150,356.8 | 596,387.3 | 130,092.9 | 138,412.8 | 145,353.3 | 142,585.6 | 540,239.6 |
| EBITDA | 39,611.2 | 44,154.9 | 184,090.0 | 47,468.4 | 46,884.4 | 49,105.0 | 41,286.6 | 179,126.4 |
| EBIT | 21,264.6 | 20,557.8 | 110,326.1 | 35,175.2 | 33,585.9 | 34,283.5 | 27,389.5 | 126,398.4 |
| EBIT-% | 15.5 % | 13.7 % | 18.5 % | 27.0 % | 24.3 % | 23.6 % | 19.2 % | 23.4 % |
| Profit before taxes | 18,457.6 | 16,821.9 | 95,855.6 | 32,571.1 | 29,938.2 | 31,039.8 | 24,179.7 | 114,064.8 |
| Net income | 14,469.2 | 15,145.7 | 77,657.3 | 27,965.9 | 23,437.4 | 24,255.9 | 21,420.5 | 94,115.9 |
Login required
This content is only available for logged in users